FDA rejects Capricor Duchenne therapy, a decision that was a long time coming
Key Points:
- The FDA has rejected deramiocel, a cell therapy developed by Capricor Therapeutics for Duchenne muscular dystrophy patients.
- The treatment targeted teenagers and young men with Duchenne who had lost the ability to walk and currently have limited treatment options.
- Two randomized clinical trials conducted by Capricor failed to demonstrate that deramiocel could prevent heart failure or preserve muscle function.
- The decision highlights the complexities involved in regulating drugs for Duchenne, a progressive muscle-wasting disease.